In vitro and in vivo activity of cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2, a mu opioid receptor agonist biased toward β-arrestin.
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Your vote was cast
Thank you for your feedback
Thank you for your feedback
AffiliationNofer Institute of Occupational Medicine
MetadataShow full item record
AbstractMorphine and related drugs, which are the most effective analgesics for the relief of severe pain, act through activating opioid receptors. The endogenous ligands of these receptors are opioid peptides which cannot be used as antinociceptive agents due to their low bioactivity and stability in biological fluids. The major goal of opioid research is to understand the mechanism of action of opioid receptor agonists in order to improve therapeutic utility of opioids. Analgesic effects of morphine are mediated mostly through activation of the mu opioid receptor. However, in the search for safer and more effective drug candidates, analogs with mixed opioid receptor profile gained a lot of interest. Recently, the concept of biased agonists able to differentially activate GPCR downstream pathways, became a new approach in the design of novel drug candidates. It is hypothesized that compounds promoting G-protein signaling may produce analgesia while β-arrestin recruitment may be responsible for opioid side effects. In this report we showed that replacement of the tyrosine residue in the mu-selective ligand Tyr-c[d-Lys-Phe-Asp]NH2 with 2',6'-dimethyltyrosine (Dmt) produced a cyclopeptide Dmt-c[d-Lys-Phe-Asp]NH2 with mu/delta opioid receptor agonist profile. This analog showed improved antinociception in the hot-plate test, probably due to the simultaneous activation of mu and delta receptors but also significantly inhibited the gastrointestinal transit. Using the bioluminescence resonance energy transfer (BRET) assay it was shown that this analog was a mu receptor agonist biased toward β-arrestin. β-Arrestin-dependent signaling is most likely responsible for the observed inhibition of gastrointestinal motility exerted by the novel cyclopeptide.
CitationPeptides 2018, 105:51-57
SponsorsThis work was supported by the Polpharma Scientific Foundation grant (11/XIII/2014 to KG) and grants from the Medical University of Lodz (No 503/1-156-02/503-11-002 and 502-03/1-156-02/502-14-301) and from the University of Ferrara (FAR grant to G.C.). KG is recipients of the Polish L’Oréal UNESCO Awards for Women in Science.
The following license files are associated with this item:
- Cyclopeptide Dmt-[D-Lys-p-CF<sub>3</sub>-Phe-Phe-Asp]NH<sub>2</sub>, a novel G protein-biased agonist of the mu opioid receptor.
- Authors: Piekielna-Ciesielska J, Ferrari F, Calo' G, Janecka A
- Issue date: 2018 Mar
- Bioactivity of new mu and delta opioid peptides.
- Authors: Capasso A
- Issue date: 2007 Sep
- Antinociceptive potency of a fluorinated cyclopeptide Dmt-c[D-Lys-Phe-p-CF<sub>3</sub>-Phe-Asp]NH<sub>2</sub>.
- Authors: Piekielna-Ciesielska J, Mollica A, Pieretti S, Fichna J, Szymaszkiewicz A, Zielińska M, Kordek R, Janecka A
- Issue date: 2018 Dec
- N-terminal guanidinylation of TIPP (Tyr-Tic-Phe-Phe) peptides results in major changes of the opioid activity profile.
- Authors: Weltrowska G, Nguyen TM, Chung NN, Wilkes BC, Schiller PW
- Issue date: 2013 Sep 15
- Redoubling the ring size of an endomorphin-2 analog transforms a centrally acting mu-opioid receptor agonist into a pure peripheral analgesic.
- Authors: Piekielna J, De Marco R, Gentilucci L, Cerlesi MC, Calo' G, Tömböly C, Artali R, Janecka A
- Issue date: 2016 May